Rehabilitative technology use among individuals with Duchenne/Becker muscular dystrophy

Romitti P. , Zhu Y. , Puzhankara S. , James K. , Nabukera S. , Zamba G. , Ciafaloni E. , Cunniff C. , Druschel C. , Mathews K. , Matthews D. , Meaney F. , Miller L. , Andrews J. , Caspers Conway K. , Fox D. , Street N. and Adams M. , Bolen J on behalf of the MD STARnet: Population-based prevalence of Duchenne and Becker muscular dystrophies in the United States, Pediatrics 135(3) (2015), 513-521.

Emery A.E. , Duchenne Muscular Dystrophy, 2nd ed. USA: Oxford University Press, 1993, p. 408.

Manzur A.Y. , Kuntzer T. , Pike M. and Swan A. , Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2004: CD003725.

Manzur A.Y. , Kuntzer T. , Pike M. and Swan A. , Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008: CD003725.

Balaban B. , Matthews D.J. , Clayton G.H. and Carry T. , Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect, Am J Phys Med Rehabil 84 (2005), 843-850.

Biggar W.D. , Harris V.A. , Eliasoph L. and Alman B. , Long-term benefits of Deflazacort treatment of boys with Duchenne muscular dystrophy in their second decade, Neuromuscul Disord 16 (2006), 249-255.

King W.M. , Ruttencutter R. , Nagaraja H.N. , Matkovic V. , Landoll J. , Hoyle C. et al., Orthopedic outcomes of long term daily corticosteroid treatment in Duchenne muscular dystrophy, Neurology 68 (2007), 1607-1613.

Houde S. , Filiatrault M. , Fournier A. , Dubé J. , D'Arcy S. , Bérubé D. et al., Deflazacort use in Duchenne muscular dystrophy: An 8 year follow up, Pediatr Neurol 38 (2008), 200-206.

Moxley III R.T. , Pandya S. , Ciafaloni E. , Fox D.J. and Campbell K. , Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: Implications for management, J Child Neurol 25 (2010), 1116-1129.

Lebel D.E. , Corston J.A. , McAdam L.C. , Biggar W.D. and Alman B.A. , Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: Long-term follow-up, J Bone Joint Surg Am 95 (2013), 1057-1061.

Silversides C.K. , Webb G.D. , Harris V.A. and Biggar D.W. , Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy, Am J Cardiol 91 (2003), 769-772.

Markham L.W. , Kinnett K. , Wong B.L. , Woodrow Benson D. and Cripe L.H. , Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy, Neuromuscul Disord 18 (2008), 365-370.

Schram G. , Fournier A. , Leduc H. , Dahdah N. , Therien J. , Vanasse M. et al., All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy, J Am Coll Cardiol 61 (2013), 948-954.

Barber B.J. , Andrews J.G. , Lu Z. , West N.A. , Meaney F.J. , Price E.T. et al., Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy, J Pediatr 163 (2013), 1080-1084.

Moxley III R.T. , Ashwal S. , Pandya S. , Connolly A. , Florence J. , Mathews K. et al., Practice parameter: corticosteroid treatment of Duchenne dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Neurology 64 (2005), 13-20.

Bushby K. , Finkel R. , Birnkrant D.J. , Case L.E. , Clemens P.R. , Cripe L. et al., Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management, Lancet Neurol 9 (2010), 77-93.

Eagle M. , Baudouin S.V. , Chandler C. , Giddings D.R. , Bullock R. and Bushby K. , Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation, Neuromuscul Disord 12 (2002), 926-929.

Jeppesen J. , Green A. , Steffensen B.F. and Rahbek J. , The Duchenne muscular dystrophy population in Denmark, 1997-2001: prevalence, incidence and survival in relation to the introduction of ventilator use, Neuromuscul Disord 13 (2003), 804-812.

McAdam L.C. , Mayo A.L. , Alman B.A. and Biggar W.D. , The Canadian experience with long term Deflazacort treatment in Duchenne muscular dystrophy, Acta Myol 31 (2012), 16-20.

Passamano L. , Taglia A. , Palladino A. , Viggiano E. , D'Ambrosio P. , Scutifero M. et al., Improvement of survival in Duchenne Muscular Dystrophy: Retrospective analysis of 835 patients, Acta Myol 31 (2012), 121-125.

Kieny P. , Chollet S. , Delalande P. , Le Fort M. , Magot A. , Pereon Y. et al., Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011, Ann Phys Rehabil Med 56 (2013), 443-454.

Henricson E.K. , Abresch R.T. , Cnaan A. , Hu F. , Duong T. , Arrieta A. et al., The cooperative international neuromuscular rearearch group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures, Muscle Nerve 48 (2013), 55-67.

Vignos P.J. , Wagner M.B. , Karlinchak B. and Katirji B. , Evaluation of a program for long-term treatment of Duchenne muscular dystrophy. Experience at the University Hospitals of Cleveland, J Bone Joint Surg Am 78 (1996), 1844-1852.

McDonald C.M. , Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics and surgery, Phys Med Rehabil Clin N Am 9 (1998), 187-211.

Bushby K. , Finkel R. , Birnkrant D.J. , Case L.E. , Clemens P.R. , Cripe L. et al., Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care, Lancet Neurol 9 (2010), 177-189.

Landfeldt E. , Lindgren P. , Bell C.F. , Schmitt C. et al., Compliance to care guidelines for Duchenne Muscular Dystrophy, Journal of Neuromuscular Diseases 2 (2015), 63-72.

Daroglu I.A. , Gur G. , Bek N. et al., is there any relation-\linebreak ship between orthotic usage and functional activities in children with neuromuscular disorders, Prostet Orthot Int 38(1) (2014), 27-33.

Bakker J.P. , de Groot I.J. , De Jong B.A. , Van Tol-De Jager M.A. and Lankhorst G.J. , Prescription pattern for orthosis in the Netherlands: Use and experience in the ambulatory phase of Duchenne muscular dystrophy, Disabil Rehabil 19 (1997), 318-325.

Garralda M.E. , Muntoni F. , Cunniff A. and Caneja A.D. , Knee ankle foot orthosis in children with Duchenne muscular dystrophy: User views and adjustment, Eur J Pediatr Neurol 10(4) (2006), 186-191.

Kumar A. and Phillips M.F. , Use of powered mobile arm supports by people with neuromuscular conditions, J Reahabil Res Dev 50(1) (2013), 61-70.

Hamilton S.J.N. , Russell P. et al., The Golden Freeway: A preliminary evaluation of a pilot study advancing information technology as a social intervention for boys with Duchenne muscular dystrophy and their families, Health Soc Care Community 12(1) (2004), 25-33.

Bakker J.P. , de Groot I.J. , De Jong B.A. , Van Tol-De Jager M.A. and Lankhorst G.J. , The effects of knee-ankle foot orthosis in the treatment of Duchenne muscular dystrophy: Review of the literature, Clin Rehabil 14 (2000), 343-359.

Rose K.J. , Burns J. , Wheeler D.M. and North K.N. , Interventions for increasing ankle range of motion in patients with neuromuscular disease. Cochrane database of systematic reviews 2010, Issue 2. Art No CD006973.

Larkindale J. , Yang W. , Hogan P.F. et al., Cost of Illness for neuromuscular diseases in the United States, Muscle Nerve 49(3) (2014), 431-438.

Landfelt E. , Lindgren P. , Bell C.F. et al., The burden of Duchenne muscular dystrophy. An international cross sectional study, Neurology 83 (2014), 529-536.

Miller L.A. , Romitti P.A. , Cunniff C. , Druschel C. , Mathews K.D. , Meaney F.J. et al., The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology, Birth Defects Res A Clin Mol Teratol 76 (2006), 793-797.

Mathews K.D. , Cunniff C. , Kantamneni J.R. , Ciafaloni E. , Miller T. , Matthews D. et al., Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): Case definition in surveillance for childhood-onset Duchenne/Becker muscular dystrophy, J Child Neurol 25 (2010), 1098-1102.

Nabukera S.K. , Romitti P.A. , Campbell K.A. , Meaney F.J. , Caspers K.M. , Mathews K.D. et al., Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy, J Child Neurol 27 (2012), 734-740.

American Association for Public Opinion Research. Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. 7th edition, Deerfield, Ill.

Zhu Y. , Romitti P.A. , Conway K.M. , Andrews J. , Liu K. , Meaney F.J. et al., Complementary and Alternative medicine for Duchenne and Becker muscular dystrophies: Characteristics of users and caregivers, Pediatr Neurol 51 (2014), 71-77.